May 1, 2018 · Since then, Lassa fever has been shown to be prevalent in many West African countries, such as Benin, Ghana, Guinea, Liberia, Mali, Nigeria, and Sierra Leone. In these countries, both …

Aug 26, 2024 · For these reasons, Lassa fever is featured in the World Health Organization’s R&D Blueprint and requires urgent action due to its potential to cause an outbreak of international concern.

The Lassa end-to-end (E2E) Access Roadmap outlines a coordinated pathway to ensure equitable access to licensed Lassa fever vaccines, outlining what is needed and who does what to ultimately …

An advanced draft of the Lassa Fever R&D Roadmap was published on the WHO website in January 2019 (WHO 2019). The roadmap included a set of strategic goals and milestones for generating …

This research agenda aims to guide and mobilise efforts toward generating timely, relevant, and actionable evidence to support Lassa fever vaccine policy- and decision-making on introducing and …

these vaccines for people who need them during outbreaks. Initially focusing on five priority pathogens from the World Health Organization (WHO) Research and Development (R&D) Blueprint (WHO …

“Given its risks to public health and recognition on the WHO’s list of priority diseases in need of urgent R&D, Lassa fever is one of CEPI’s vaccine targets”, explains Dr Richard Hatchett, CEO of the …

AMR is the consequence of antimicrobial consumption and especially wrong, partial and irrational consumption. Any intervention that reduces our need to use antimicrobials including reducing the ...

Vaccinating the populations concerned is therefore the most promising strategy to deal with recurrent outbreaks of Lassa fever. The World Health Organization (WHO) has included Lassa fever in its …

Sep 3, 2024 · This modelling study highlights the burden of Lassa fever and its significant socioeconomic consequences, underscoring the urgent need to accelerate vaccine research and …